Cancer clinical trials in the region Occitanie

369 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Early Access Liver and bile duct cancer

Accès précoce post-AMM - ZIIHERA (Zanidatamab)

Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Locally Advanced Metastatic HER2 1 2 3 or more Chemotherapy

Systemic Treatment-Naive

1 recruiting site

Jazz Pharmaceuticals

Early Access Bladder / Urinary Tract / Urethral cancer

Accès précoce post-AMM– KEYTRUDA (Pembrolizumab)

Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive

1 recruiting site

Merck Sharp & Dohme LLC

Early Access Bladder / Urinary Tract / Urethral cancer

Accès précoce post-AMM - PADCEV (Enfortumab vedotin)

Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive

1 recruiting site

Astellas Pharma Développement mondial, Inc.

Early Access Kidney cancer Pancreas cancer

Accès précoce post-AMM - WELIREG (Belzutifan)

Clear cell carcinoma Neuroendocrine tumor Localized Von Hippel-Lindau syndrome (VHL)

1 recruiting site

Merck Sharp & Dohme LLC

Early Access Lymphoma

Accès précoce post-AMM – COLUMVI (Glofitamab)

B cell lymphoma Large B cell lymphoma 2 3 or more

Systemic Treatment-Naive

1 recruiting site

Hoffmann-La Roche

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT (Amivantamab)

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy

Systemic Treatment-Naive

1 recruiting site

Janssen

Phase 3 Lung cancer #NCT07431827

[KANDLELIT-013] MK-3475A±Calderasib (MK-1084) dans le CBNPC de stade IIA-IIIB (N2) KRAS G12Cm complètement réséqué (MK-1084-013)

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Localized KRAS G12C None Systemic Treatment-Naive Surgery Immunotherapy Chemotherapy

1 recruiting site

Merck Sharp & Dohme LLC

Phase 3 Sarcoma and GIST #NCT07218926 #2025-522229-37-00

Étude comparant l'IDRX-42 (GSK6042981) au sunitinib chez des participants atteints de tumeurs stromales gastro-intestinales après un traitement par imatinib.

GIST Locally Advanced Metastatic KIT PDGFRA 1 Targeted therapy

Systemic Treatment-Naive

8 recruiting sites

GlaxoSmithKline

Phase 3 Lung cancer #NCT07185997 #2025-522151-26-00

Étude visant à évaluer l'efficacité et l'innocuité du firmonertinib par rapport à un inhibiteur de l'EGFR choisi par l'investigateur en tant que traitement de première ligne chez des participants atteints d'un CBNPC localement avancé ou métastatique présentant des mutations rares de la boucle P et de l'hélice C alpha de l'EGFR (PACC)

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

Targeted therapy Bispecific T-cell engager antibodies

6 recruiting sites

ArriVent BioPharma, Inc

Phase 3 Endometrial cancer #NCT07044336 #2024-518777-34-00

[Bluestar-Endometrial01] Comparaison de PUXITATUG SAMROTECAN en monothérapie et de chimiothérapie dans le cancer de l'endomètre sélectionné pour B7-H4

Locally Advanced Metastatic 1 2 Immunotherapy Chemotherapy

Systemic Treatment-Naive

13 recruiting sites

AstraZeneca